2007: RA: Clinical Aspects I
Search or Browse by Day

RA: Clinical Aspects I

292
Targeting the IL-6 Receptor with the Monoclonal Antibody Tocilizumab Significantly Improves Quality of Life in Patients with Rheumatoid Arthritis
293
High Proportion of Remission Can be Achieved Using Initial Early Optimal DMARD Therapy in Patients with New Onset Inflammatory Arthritis
294
Change Over Time in the Safety, Efficacy, and Remission Profiles of Patients With Rheumatoid Arthritis Receiving Adalimumab for Up to 7 Years
295
Comparable Response Rates Between First and Second anti-TNFα Therapies in Rheumatoid Arthritis Patients under Treatment with anti-TNF agents
296
Long-term Safety and Efficacy of Tocilizumab (anti-IL-6 Receptor Monoclonal Antibody) in Monotherapy, in Patients with Rheumatoid Arthritis
297
Switching between Anti-TNFs: A Comparison of Maximum Efficacy with Each Treatment - Data from the STURE Registry
298
Disease Activity in the Early Course of Treatment Predicts Long-Term Response to Therapy in Rheumatoid Arthritis Patients
299
Effectiveness of Switch to a Second AntiTNFα in Primary Nonresponders, Secondary Nonresponders and Failure Due to Adverse Events
300
Predictors of Drug Free Remission in Patients with Recent-Onset Rheumatoid Arthritis Receiving Das-Guided Treatment in the BeSt Study
301
Clinical and Laboratory Features after Orthopedic Surgery in Tocilizumab-Treating Patients with Rheumatoid Arthritis
302
Factors Influencing Functional Disability in Patients with RA Who Are in Remission Following 5 Years of Treatment with Adalimumab (ADA) Plus Methotrexate (MTX)
303
Evaluating the Effectiveness and Safety of Etanercept in Subjects with Rheumatoid Arthritis Who Have Failed Infliximab Therapy: EMBARK, an Open-Label Observational Study
304
Increased Independence in RA Patients: A Multidimensional Assessment from the ATTAIN Trial
305
Patients with Rheumatoid Arthritis Who are Non-Responders to Etanercept Plus Methotrexate Therapy at Week 12 Achieve a Response at Week 24 and Sustain the Gain in Response
306
Anti-TNF Treatment: Reasons for Concern and Discontinuation among Rheumatoid Arthritis Patients
307
Response to Infliximab Therapy is Related to Pretreatment Tissue Inflammation Levels in Rheumatoid Arthritis Patients: Results from Large-Scale Gene Expression Profiling
308
Differences in Selection Criteria and Clinical Outcomes to Anti-TNFα Therapy in Patients with Rheumatoid Arthritis in Two European Countries
309
Safety and Pharmacodynamics of Repeat Administration of TRU-015, a CD20-Directed SMIP™ Therapeutic, in Subjects with Rheumatoid Arthritis
310
Hepatotoxicity Associated with Non-Biologic DMARDs: Implications for Evaluation of New Rheumatic Disease Therapies
311
Efficacy of Low Dose Prednisone (1-4 mg/day) in Patients with Rheumatoid Arthritis: A Randomized Controlled Placebo Controlled Double-Blind Withdrawal Trial
312
Efficient Management of Disease Activity in Patients with Early RA Significantly Reduces Long-Term Functional Disability
313
Managing RA Disease Activity Efficiently without Long-Term Corticosteroid Use Results in Better Functional Outcomes in Patients with Early RA
314
Treatment with Anti-TNFalpha Antagonists in Patients with Rheumatoid Arthritis Results in a Significant Decrease of Concomitant Glucocorticoid Therapy
315
Etanercept Therapy in Patients with Positive Hepatitis C Serology
316
Absence of Transaminase Elevation During Concomitant Methotrexate and Isoniazid Therapy
317
Reduction of Bone Damage by Calcineurin-Inhibitors in Patients with Rheumatoid Arthritis
318
A Comparison of the Lifetime Health Benefits of Etanercept Versus Abatacept Following anti-TNF Treatment in Patients With Rheumatoid Arthritis
319
Lifetime Health Benefits of Etanercept Compared Against Abatacept Following Failure of Methotrexate
320
Early Treatment with and Time on First Disease Modifying Anti-Rheumatic Drug Predicts Long Term Functional Outcome in Patients with Inflammatory Polyarthritis
321
The Relationship between Function and Radiological Damage in Early Rheumatoid Arthritis (ra) - A Longitudinal Analysis from the Eras Cohort
322
Association of TNF-α -308 G/A Polymorphism with Responsiveness to TNF- α Blockers in Rheumatoid Arthritis: A Meta-Analysis
323
The Outcome of Aggressive Biologic Therapy in Clinical Practice: Measurement by DAS Remission and Minimal Disease Activity (MDA).
324
Tapering Infliximab Dosages after Temporary Dose Increase Does Not Affect Treatment Survival in an Established RA Population
325
Spontaneous Amelioration in Early, Dmard Naive Patients with Rheumatoid Arthritis: Role of Antibody Profiles and Carriage of the Hla Shared Epitope in Predicting Decrease of Disease Activity.
326
Clinical Predictors of Persistent Arthritis after Six Months in Patients with Arthritis of Less Than 16 Weeks Duration
327
Different Relationships Exist between Radiographic Progression and Clinical Status for Adalimumab (ADA) Plus Methotrexate (MTX) vs. ADA or MTX Monotherapy: Subanalysis of PREMIER
328
Anxiety is Correlated with Clinical Conditions of Rheumatoid Arthritis and Improved by Anti-TNF Alpha Therapy
329
Improvement of Depressive States Seen in Patients with Rheumatoid Arthritis by Infliximab Treatment: Potential Involvements of Inflammatory Cytokines and Hormones
330
Differential Swollen and Tender Joint Count Responses Following Anti-TNF Therapy in Rheumatoid and Psoriatic Arthritis
331
A Single Centre Experience of Treating Rheumatoid and Psoriatic Arthritis with Biologics Therapy in the Republic of Ireland
332
Clinical Factors Associated with the Use of Rituximab in Patients with Initial Treatment Failure to Tnf Inhibitors in Ra and Physician Election, First Year Data from the Mirar Study
333
Variation in the Proportion of Patients in Standard Care in 58 Clinical Sites in 21 Countries who Meet DAS28 >5.1 Critreria for High Diesase Activity; Data From the QUEST-RA Database
334
Infusion Reactions with Infliximab: Rapid versus 2 Hours Infusion
335
Predicting Response to Anti-TNF Therapy in Patients with Inflammatory Arthritis Using Measures of Autonomic Reactivity: an Exploratory, Double-Blind Study with Heart Rate Variability
336
Alcohol Consumption is Related with Better Response to DMARD Therapy for Early Rheumatoid Arthritis in Men But Not in Women
337
Population Analysis of Denosumab Pharmacokinetics (PK) and Pharmacodynamics (PD) in Patients With Rheumatoid Arthritis (RA)
338
Functional and Work Outcomes Improve in RA Patients Who Receive Timely Comprehensive Occupational Therapy
339
Prescription Practice Of Biologics In Rheumatoid Arthritis Is Changing Over Time. Does That Affect The EULAR Treatment Response? Results From The Nationwide DANBIO Registry
340
Tight Control in the Treatment of Rheumatoid Arthritis: A New Paradigm
341
Contemporary Trends in Rheumatoid Arthritis Disease Activity Reduction and Medication Use
342
Leflunomide is an acceptable Combination Partner for TNF Inhibitors if Methotrexate is not Tolerated - Results from the German Biologics Register
343
Effect of Rheumatoid Factor (RF) Levels on Response to Standard Dmard-Combination Treatment in Patients with Rheumatoid Arthritis (RA)
344
Safety Outcomes from a Large Japanese Post-Marketing Surveillance for Etanercept
345
Should Local Anesthesia be used with Arthrocentesis and Joint Procedures?
346
Effect of Progressive Resistance Training in Cachectic Rheumatoid Arthritis Patients
347
The Safety of Re-infusion of Infliximab in RA Patients: Results from the Post-Marketing Surveillance (PMS) in Japan
348
Failure of Adalimumab in Patients with Rheumatoid Arthritis
349
Study of Relationship between Disase Activity and Autoantibodies in Patients with Rheumatoid Arthritis during Infliximab Therapy
350
Adverse Events on Patients Diagnosed with Rheumatoid Arthitis under Anti-tnf Treatment
351
The Value of Convenience: Are Patients Willing to Trade-Off Other Attributes of Treatment for Better Convenience?
352
Acupuncture for Pain Relief in Patients with Rheumatoid Arthritis: A Systematic Review
353
Early Achievement of American College of Rheumatology (acr) 70% Improvement Criteria at 6 Weeks Predicts Therapeutic Efficacy at 2 Years in Active Rheumatoid Arthritis (ra) Patients Treated by Infliximab with Concomitant Use of Low Dose Methotrexate (mtx)
354
The Utility of an Early Arthritis Clinic for Improving Time to Treatment
355
Disease Activity at Baseline and Early Treatment Response Predict Long-Term Success of Therapy In Rheumatoid Arthritis - Results from an Observational Study
356
The Efficacy of Infliximab Treatment in 5,000 Patients with Rheumatoid Arthritis: Results from the Post Marketing Surveillance Study in Japan
See more of: ACR Abstract Submission Poster Sessions
<< Previous Session Level | Next Session Level >>